PHAT — Phathom Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $567.12m
- $934.14m
- $175.11m
Brief: Phathom Pharmaceuticals Q2 Net Income USD -91.446 Million
Brief: Phathom Pharmaceuticals Announces FDA Approval Of Voquezna® (Vonoprazan) Tablets For The Relief Of Heartburn Associated With Non-Erosive Gerd In Adults
Brief: Phathom Pharmaceuticals Q1 Net Income USD -82.852 Million
Phathom Pharmaceuticals Inc expected to post a loss of $1.31 a share - Earnings Preview
Brief: Takeda Pharmaceutical Co Ltd Reports Stake Of 5.4% In Phathom Pharmaceuticals Inc As Of March 28
Phathom Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Phathom Pharmaceuticals Q4 Net Income USD -79.569 Million
Phathom Pharmaceuticals Inc expected to post a loss of $1.08 a share - Earnings Preview
Brief: Takeda Pharmaceutical Reports 6.6% Stake In Phathom Pharmaceuticals
Brief: Phathom Pharmaceuticals Entered Into Fourth Amendment To Loan And Security Agreement With Hercules Capital - SEC Filing
Brief: Phathom Pharmaceuticals Announces Expansion Of Existing Loan And Security Agreement With Hercules Capital
Brief: Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
Brief: Phathom Pharmaceuticals Announces Commercial Availability Of Voquezna® (Vonoprazan) Tablets, A Powerful First-In-Class Pcab For The Treatment Of Erosive Gerd And Relief Of Associated Heartburn
U.S. RESEARCH ROUNDUP-Boot Barn Holdings, Hershey Co, Ulta Beauty
Brief: Phathom Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing
Brief: Phathom Pharmaceuticals Q3 Net Income USD -43.243 Million
Phathom Pharmaceuticals Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Phathom Pharmaceuticals Announces Vonoprazan NDA Submission For Non-Erosive Gerd
U.S. STOCKS ON THE MOVE-Natgas firms, Moderna, VinFast